View Older Stories
-
Needham Downgrades Cidara Therapeutics (CDTX) to Hold
-
H.C. Wainwright Downgrades Cidara Therapeutics (CDTX) to Neutral
-
Increasing unusual call option volume: CDTX UDN CNP EU IVVD XP CWAN SSRM GLNG GLBE AIG AVDX
-
Merck to acquire Cidara for $9.2 billion to gain influenza drug
-
Cidara Therapeutics (CDTX) call put ratio 3.4 calls to 1 put
-
Merck (MRK) Nearing Deal To Buy Cidara Therapeutics- FT
-
Cidara Therapeutics (CDTX) Misses Q3 EPS by 310c
-
H.C. Wainwright Reiterates Buy Rating on Cidara Therapeutics (CDTX)
-
Cidara presents CD388 influenza data at European conference
-
Citizens Reiterates Cidara Therapeutics (CDTX) at Market Outperform After CD388 Phase 2 Trial
-
Morgan Stanley Starts Cidara Therapeutics (CDTX) at Overweight
-
Cidara Therapeutics (CDTX) PT Raised to $150 at H.C. Wainwright
-
JPMorgan Starts Cidara Therapeutics (CDTX) at Overweight
-
H.C. Wainwright Reiterates Buy Rating on Cidara Therapeutics (CDTX)
-
Cidara Therapeutics (CDTX) PT Raised to $173 at Citizens
-
Cidara receives up to $339 million BARDA award for influenza drug development
-
Cidara Therapeutics (CDTX) PT Raised to $167 at Guggenheim
-
H.C. Wainwright Reiterates Buy Rating on Cidara Therapeutics (CDTX)
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
Cidara Therapeutics (CDTX) PT Raised to $123 at WBB Securities
-
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
Cidara Therapeutics (CDTX) PT Raised to $66 at Citizens JMP
-
Cidara Therapeutics (CDTX) PT Raised to $70 at Guggenheim
-
Cidara Therapeutics (CDTX) PT Raised to $66 at Citizens JMP
-
Cidara Therapeutics (CDTX) PT Raised to $115 at RBC Capital
-
Cidara Therapeutics (CDTX) PT Raised to $69 at Guggenheim
-
Citizens JMP Reiterates Market Outperform Rating on Cidara Therapeutics (CDTX)
-
Cidara Therapeutics (CDTX) PT Raised at RBC Capital; 'Would Be Buyers Into Strength'
-
Cidara Therapeutics (CDTX) PT Raised to $68 at Guggenheim
-
Cidara Therapeutics (CDTX) PT Raised to $53 at H.C. Wainwright
-
Cidara Therapeutics (CDTX) Announces Proposed $250M Share Offering
-
Cidara Therapeutics (CDTX) Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza
-
H.C. Wainwright Assumes Cidara Therapeutics (CDTX) at Buy
-
Cantor Fitzgerald Reiterates Overweight Rating on Cidara Therapeutics (CDTX)
-
Citizens JMP Reiterates Market Outperform Rating on Cidara Therapeutics (CDTX)
-
Cidara Therapeutics (CDTX) PT Raised to $36 at Needham
-
Citizens JMP Reiterates Market Outperform Rating on Cidara Therapeutics (CDTX)
-
Citizens JMP Reiterates Market Outperform Rating on Cidara Therapeutics (CDTX)
-
Cidara Therapeutics (CDTX) July 17.50 puts and July 20 calls active
-
Cidara Therapeutics (CDTX) PT Raised to $47 at Citizens JMP
-
Cidara Therapeutics (CDTX) Appoints Nicole Davarpanah as Chief Medical Officer
-
Citizens JMP Reiterates Market Outperform Rating on Cidara Therapeutics (CDTX)
-
Phathom Pharmaceuticals Inc. (PHAT) Appoints Ted Schroeder to its Board of Directors
-
Cantor Fitzgerald Reiterates Overweight Rating on Cidara Therapeutics (CDTX)
-
Citizens JMP Starts Cidara Therapeutics (CDTX) at Market Outperform
-
Cidara Therapeutics (CDTX) PT Raised to $35 at H.C. Wainwright
-
Cidara Therapeutics (CDTX) Misses Q4 EPS by 537c
-
Cidara Therapeutics (CDTX) Appoints Frank Karbe as CFO
-
Cantor Fitzgerald Assumes Cidara Therapeutics (CDTX) at Overweight

